Biopharmaceutical company Gilead Sciences Inc (Nasdaq:GILD) on Thursday released topline results from an interim analysis of a Phase 3 trial indicating that the company's twice-yearly injectable HIV-1 capsid inhibitor, lenacapavir, is more effective in preventing HIV infection in women compared to its existing daily pill, Truvada.

Gilead said that there were zero cases of HIV infection among women who were treated with lenacapavir. More detailed data will be presented at a later date.

Truvada, a combination of tenofovir and emtricitabine, can treat HIV and is also used in a prevention regimen known as pre-exposure prophylaxis (PrEP).